Regentis Biomaterials Ltd. (NYSE American: RGNT) is making strides in regenerative orthopedic care with its lead product GelrinC, a cell-free, off-the-shelf hydrogel designed to regenerate damaged knee cartilage. Unlike traditional implants that replace or reinforce damaged tissue, GelrinC is injected into the cartilage lesion and cured in place with ultraviolet light, creating a temporary scaffold that supports the body’s natural healing process. As new tissue develops, the hydrogel gradually degrades, leaving behind regenerated cartilage.
The company has reported encouraging clinical results, including greater pain improvement compared to microfracture at two years and MRI evidence of cartilage regeneration. These findings suggest that GelrinC could offer a more effective and durable solution for patients suffering from cartilage defects, potentially delaying or avoiding the need for joint replacement surgery.
GelrinC already holds CE Mark approval in Europe, allowing Regentis to prepare for commercialization in that market. In the United States, the pivotal Phase III SAGE study has surpassed 50% enrollment, marking a significant milestone toward potential FDA approval. If successful, GelrinC would address a substantial unmet need, as there are approximately 470,000 cases of knee cartilage repair annually in the U.S., with no off-the-shelf treatment currently available.
Another key development is a new manufacturing process that improves production yield by 400%. This could enhance scalability and reduce costs, making it more feasible to meet the demand if the product gains regulatory approval. According to the company, this advancement supports future growth as Regentis works to bring GelrinC to a broader patient population.
GelrinC is based on Regentis’ Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The product is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled manner.
For more information on Regentis Biomaterials and its progress, visit the company’s newsroom at https://nnw.fm/RGNT. The full article can be found at https://nnw.fm/cWmZ7.
